Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2022-01-20 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于提前归还可转债部分暂时补充流动资金的募集资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the early repayment of part of the funds raised through convertible bonds temporarily used to supplement working capital. It discusses the use and repayment of raised funds, referencing previous announcements and compliance with disclosure obligations. The document is short (946 characters) and focuses on a specific financing activity update rather than a full financial report or detailed financial statements. It does not contain comprehensive financial data or results, nor is it a regulatory certification or voting result. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2022-01-20 Chinese
关于公司完成注册资本工商变更登记及章程备案的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the completion of registration capital change and amendment of the company's articles of association. It references board and shareholder meetings where the capital change was approved and states that the company has completed the registration and obtained the updated business license. The document is short (838 characters) and serves as a formal notice of a capital change and related filings, not a detailed financial report or presentation. It does not contain financial statements or detailed analysis, but rather an official announcement of a capital change and related corporate registration update. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2022-01-17 Chinese
2021年度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a '2021年度业绩预告' which translates to '2021 Annual Performance Forecast'. It provides preliminary profit estimates for the full year 2021, including net profit attributable to shareholders and earnings per share. It explicitly states that the data is preliminary, unaudited, and based on internal estimates by the finance department. It also mentions that the final detailed financial data will be disclosed in the 2021 annual report. The document is short (1335 characters) and serves as a performance forecast announcement rather than a full financial report. This fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results highlighting key figures but not the full report. It is not an Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements and detailed analysis. It is not a Report Publication Announcement (RPA) because it contains substantive preliminary financial data rather than just announcing a report's release. Therefore, the correct classification is Earnings Release (ER). FY 2021
2022-01-12 Chinese
2021年第四季度可转换公司债券转股情况公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the convertible bonds (可转换公司债券) of 特一药业集团股份有限公司 for the fourth quarter of 2021. It details the bond issuance, adjustments to the conversion price, and the changes in shareholding due to bond conversions during the quarter. The document includes regulatory references to the Shenzhen Stock Exchange and China Securities Regulatory Commission approvals. The length is 2764 characters, which is relatively short and the document is primarily an announcement of bond conversion activity and shareholding changes, not a full financial report or audit. It does not contain comprehensive financial statements or detailed financial analysis. Therefore, it fits best under Capital/Financing Update (CAP), as it relates to convertible bond conversions and capital structure changes.
2022-01-05 Chinese
关于全资子公司股权投资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding its investment activities through a wholly-owned subsidiary. It details the investment in another company, the purpose, risks, and impact on the company. The document is relatively short (3022 characters) and focuses on disclosing a specific investment transaction rather than providing comprehensive financial data or results. There is no indication of financial statements, audit opinions, or detailed financial performance analysis. It is not a report like an Annual Report (10-K) or Interim Report (IR), nor is it a call transcript or management discussion. The content fits the category of a regulatory announcement about a capital investment transaction. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-12-31 Chinese
北京市君泽君（深圳）律师事务所关于特一药业集团股份有限公司2021年第二次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the legality of procedures and voting results of a specific shareholders' meeting (the 2021 second extraordinary general meeting) of a company. It details the convening, attendance, voting procedures, and results of the shareholders' meeting. It does not contain financial statements or financial performance data, nor is it a report or announcement of financial results. It is not a proxy solicitation or voting results announcement per se, but a legal opinion on the meeting's legality. This type of document is best classified under Regulatory Filings (RNS) as it is a compliance/legal document related to corporate governance and shareholder meetings but does not fit other more specific categories.
2021-12-27 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.